Agonism and antagonism at the insulin receptor.

Insulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new ins...

Full description

Bibliographic Details
Main Authors: Louise Knudsen, Bo Falck Hansen, Pia Jensen, Thomas Åskov Pedersen, Kirsten Vestergaard, Lauge Schäffer, Blagoy Blagoev, Martin B Oleksiewicz, Vladislav V Kiselyov, Pierre De Meyts
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3531387?pdf=render
id doaj-77029b21ff594f02ba9f32822e1fa7cc
record_format Article
spelling doaj-77029b21ff594f02ba9f32822e1fa7cc2020-11-25T01:57:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01712e5197210.1371/journal.pone.0051972Agonism and antagonism at the insulin receptor.Louise KnudsenBo Falck HansenPia JensenThomas Åskov PedersenKirsten VestergaardLauge SchäfferBlagoy BlagoevMartin B OleksiewiczVladislav V KiselyovPierre De MeytsInsulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new insulin analogues. The occurrence of ligand agonism and antagonism is well described for G protein-coupled receptors (GPCRs) and other receptors but in general, with the exception of antibodies, not for receptor tyrosine kinases (RTKs). In the case of the IR, no natural ligand or insulin analogue has been shown to exhibit antagonistic properties, with the exception of a crosslinked insulin dimer (B29-B'29). However, synthetic monomeric or dimeric peptides targeting sites 1 or 2 of the IR were shown to be either agonists or antagonists. We found here that the S961 peptide, previously described to be an IR antagonist, exhibited partial agonistic effects in the 1-10 nM range, showing altogether a bell-shaped dose-response curve. Intriguingly, the agonistic effects of S961 were seen only on mitogenic endpoints ((3)H-thymidine incorporation), and not on metabolic endpoints ((14)C-glucose incorporation in adipocytes and muscle cells). The agonistic effects of S961 were observed in 3 independent cell lines, with complete concordance between mitogenicity ((3)H-thymidine incorporation) and phosphorylation of the IR and Akt. Together with the B29-B'29 crosslinked dimer, S961 is a rare example of a mixed agonist/antagonist for the human IR. A plausible mechanistic explanation based on the bivalent crosslinking model of IR activation is proposed.http://europepmc.org/articles/PMC3531387?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Louise Knudsen
Bo Falck Hansen
Pia Jensen
Thomas Åskov Pedersen
Kirsten Vestergaard
Lauge Schäffer
Blagoy Blagoev
Martin B Oleksiewicz
Vladislav V Kiselyov
Pierre De Meyts
spellingShingle Louise Knudsen
Bo Falck Hansen
Pia Jensen
Thomas Åskov Pedersen
Kirsten Vestergaard
Lauge Schäffer
Blagoy Blagoev
Martin B Oleksiewicz
Vladislav V Kiselyov
Pierre De Meyts
Agonism and antagonism at the insulin receptor.
PLoS ONE
author_facet Louise Knudsen
Bo Falck Hansen
Pia Jensen
Thomas Åskov Pedersen
Kirsten Vestergaard
Lauge Schäffer
Blagoy Blagoev
Martin B Oleksiewicz
Vladislav V Kiselyov
Pierre De Meyts
author_sort Louise Knudsen
title Agonism and antagonism at the insulin receptor.
title_short Agonism and antagonism at the insulin receptor.
title_full Agonism and antagonism at the insulin receptor.
title_fullStr Agonism and antagonism at the insulin receptor.
title_full_unstemmed Agonism and antagonism at the insulin receptor.
title_sort agonism and antagonism at the insulin receptor.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Insulin can trigger metabolic as well as mitogenic effects, the latter being pharmaceutically undesirable. An understanding of the structure/function relationships between insulin receptor (IR) binding and mitogenic/metabolic signalling would greatly facilitate the preclinical development of new insulin analogues. The occurrence of ligand agonism and antagonism is well described for G protein-coupled receptors (GPCRs) and other receptors but in general, with the exception of antibodies, not for receptor tyrosine kinases (RTKs). In the case of the IR, no natural ligand or insulin analogue has been shown to exhibit antagonistic properties, with the exception of a crosslinked insulin dimer (B29-B'29). However, synthetic monomeric or dimeric peptides targeting sites 1 or 2 of the IR were shown to be either agonists or antagonists. We found here that the S961 peptide, previously described to be an IR antagonist, exhibited partial agonistic effects in the 1-10 nM range, showing altogether a bell-shaped dose-response curve. Intriguingly, the agonistic effects of S961 were seen only on mitogenic endpoints ((3)H-thymidine incorporation), and not on metabolic endpoints ((14)C-glucose incorporation in adipocytes and muscle cells). The agonistic effects of S961 were observed in 3 independent cell lines, with complete concordance between mitogenicity ((3)H-thymidine incorporation) and phosphorylation of the IR and Akt. Together with the B29-B'29 crosslinked dimer, S961 is a rare example of a mixed agonist/antagonist for the human IR. A plausible mechanistic explanation based on the bivalent crosslinking model of IR activation is proposed.
url http://europepmc.org/articles/PMC3531387?pdf=render
work_keys_str_mv AT louiseknudsen agonismandantagonismattheinsulinreceptor
AT bofalckhansen agonismandantagonismattheinsulinreceptor
AT piajensen agonismandantagonismattheinsulinreceptor
AT thomasaskovpedersen agonismandantagonismattheinsulinreceptor
AT kirstenvestergaard agonismandantagonismattheinsulinreceptor
AT laugeschaffer agonismandantagonismattheinsulinreceptor
AT blagoyblagoev agonismandantagonismattheinsulinreceptor
AT martinboleksiewicz agonismandantagonismattheinsulinreceptor
AT vladislavvkiselyov agonismandantagonismattheinsulinreceptor
AT pierredemeyts agonismandantagonismattheinsulinreceptor
_version_ 1724975293196664832